Nitroglycerin as Spasmolytic Regimen for RAS Prevention in Radial Center
NCT ID: NCT03889470
Last Updated: 2019-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
1000 participants
INTERVENTIONAL
2018-03-31
2019-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevention and Comparison of Different Forms of Administration of Nitrates in the Risk of Radial Spasm During Coronary Angiography.
NCT02258620
Randomized Clinical Trial Comparing Transradial Catheterization With or Without Spasmolytic Drugs
NCT02343276
Nicardipine to Avoid Spasm in Trans Radial Percutaneous Coronary Intervention
NCT04538534
A Validation Study of Nitroglycerin Induced Acute Drop of Pd/Pa (NTG-Pd/Pa) in Clinical Practice
NCT04700397
Safety and Tolerability of Nitro for Radial Artery Dilation
NCT05239013
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Both NTG and placebo will be administered using an identical syringe to keep the operators blinded to the treatment allocation. Radial angiogram is mandatory to measure the diameter of both radial and ulnar arteries. Doppler ultrasound of the radial artery will be examined at the day after the procedure.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
200 microgram NTG
200 microgram NTG through the radial sheath
NTG 1 MG/ML Injectable Solution
administered after sheath placement
Saline
Saline infusion through the radial sheath
NTG 1 MG/ML Injectable Solution
administered after sheath placement
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NTG 1 MG/ML Injectable Solution
administered after sheath placement
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Refuse to participate
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hermina Heart Center Kemayoran
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Surya Dharma, MD, PhD
MD, PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hermina Heart Center
Jakarta Pusat, DKI Jakarta, Indonesia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HerminaHCKRAS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.